{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:26:01Z","timestamp":1753892761410,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K12DA031794"],"award-info":[{"award-number":["K12DA031794"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alcohol and other substance use disorders are commonly associated with post-traumatic stress disorder (PTSD), and the presence of these comorbidities is associated with worse treatment outcomes. Additionally, disparities in substance and PTSD prevalence have been associated with minority races and ethnicities, and minorities have been shown to be less likely to engage in treatment. Psychedelic-assisted treatments, including 3,4-methylenedioxymethamphetamine (MDMA), have shown preliminary trans-diagnostic effectiveness, however it is unknown how individuals with substance use disorders view the therapeutic potential of MDMA therapy. Previous studies have also shown that minority races and ethnicities are under-represented in the MDMA trials, leading to concerns about inequitable access to clinical treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To explore demographic characteristics related to patient-level perspectives on the therapeutic potential of MDMA-assisted therapy, this study describes data from a nationwide, cross-sectional survey of 918 individuals self-reporting criteria consistent with alcohol or substance use disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, a majority of individuals reported support for medical research of MDMA (68.1%), belief that MDMA-assisted therapy might be a useful treatment (70.1%), and willingness to try MDMA-assisted therapy if it were determined to be an appropriate treatment for them (58.8%). No race or ethnicity differences were found in support for further research or belief in effectiveness, however there were small disparities in terms of willingness to try MDMA-assisted therapy and concerns related to use of this treatment approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results provide insights and future directions as the field of psychedelic-assisted therapy seeks to provide equitable access to clinical care and to diversify research participation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1096298","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:27:45Z","timestamp":1681446465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users"],"prefix":"10.3389","volume":"14","author":[{"given":"Jennifer L.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17734","DOI":"10.3402\/ejpt.v3i0.17734","article-title":"Prevalence of post-traumatic stress disorder among patients with substance use disorder: it is higher than clinicians think it is","volume":"3","author":"Gielen","year":"2012","journal-title":"Eur J Psychotraumatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1176\/ajp.2006.163.4.652","article-title":"Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of mental health and well-being","volume":"163","author":"Mills","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e000913","DOI":"10.1136\/tsaco-2022-000913","article-title":"Post-traumatic stress disorder (PTSD) symptoms and alcohol and drug use comorbidity at 25 US level I trauma centers","volume":"7","author":"Nguyen","year":"2022","journal-title":"Trauma Surg Acute Care Open"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1037\/adb0000355","article-title":"Alcohol, cannabis, and other drug use: engagement and outcome in PTSD treatment","volume":"32","author":"Bedard-Gilligan","year":"2018","journal-title":"Psychol Addict Behav"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1037\/adb0000348","article-title":"The burden of co-occurring alcohol use disorder and PTSD in U.S. military veterans: comorbidities, functioning, and suicidality","volume":"32","author":"Norman","year":"2018","journal-title":"Psychol Addict Behav"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s40501-019-00176-w","article-title":"Dealing with complexity and comorbidity: comorbid PTSD and substance use disorders","volume":"6","author":"Tripp","year":"2019","journal-title":"Curr Treat Options Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/A:1014894506325","article-title":"The prevalence of posttraumatic stress disorder among American Indian Vietnam veterans: disparities and context","volume":"15","author":"Beals","year":"2002","journal-title":"J Traumat Stress"},{"volume-title":"Trauma and the Vietnam war generation","year":"1990","author":"Kulka","key":"ref8"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1056\/NEJMsa013404","article-title":"Psychological sequelae of the September 11 terrorist attacks in New York City","volume":"346","author":"Galea","year":"2002","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00127-013-0759-y","article-title":"Posttraumatic stress disorder and symptoms among American Indians and Alaska natives: a review of the literature","volume":"49","author":"Bassett","year":"2014","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1017\/S0033291710000401","article-title":"Race\/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States","volume":"41","author":"Roberts","year":"2011","journal-title":"Psychol Med"},{"key":"ref12","first-page":"1","article-title":"Posttraumatic stress disorder and racial trauma","volume":"32","author":"Williams","year":"2021","journal-title":"PTSD Res Q"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jsat.2015.12.007","article-title":"Racial and ethnic disparities in outpatient substance use disorder treatment episode completion for different substances","volume":"63","author":"Mennis","year":"2016","journal-title":"J Subst Abus Treat"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addbeh.2019.01.041","article-title":"How long does it take to complete outpatient substance use disorder treatment? Disparities among blacks, Hispanics, and whites in the US","volume":"93","author":"Mennis","year":"2019","journal-title":"Addict Behav"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15332640.2022.2129537","article-title":"Racial-ethnic disparities across substance use disorder treatment settings: sources of treatment insurance, socioeconomic correlates and clinical features","volume":"21","author":"Archibald","year":"2022","journal-title":"J Ethn Subst Abus"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"108087","DOI":"10.1016\/j.drugalcdep.2020.108087","article-title":"Substance use improvement depends on race\/ethnicity: outpatient treatment disparities observed in a large US national sample","volume":"213","author":"Sahker","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/15332640.2020.1836699","article-title":"Ethnoracial differences in treatment-seeking veterans with substance use disorders and co-occurring PTSD: presenting characteristics and response to integrated exposure-based treatment","volume":"21","author":"Brown","year":"2022","journal-title":"J Ethn Subst Abus"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"109211","DOI":"10.1016\/j.neuropharm.2022.109211","article-title":"Pharmacological strategies for post-traumatic stress disorder (PTSD): from animal to clinical studies","volume":"218","author":"Gasparyan","year":"2022","journal-title":"Neuropharmacology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jcm5110105","article-title":"Posttraumatic stress disorder: overview of evidence-based assessment and treatment","volume":"5","author":"Lancaster","year":"2016","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"17462","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fpsyt.2018.00277","article-title":"Efficacy of ketamine in the treatment of substance use disorders: a systematic review","volume":"9","author":"Jones","year":"2018","journal-title":"Front Psych"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am J Psychiatr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am J Psychiatr"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"109356","DOI":"10.1016\/j.drugalcdep.2022.109356","article-title":"The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD","volume":"233","author":"Nicholas","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J Psychopharmacol"},{"year":"2021","key":"ref32"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1177\/02698811221104052","article-title":"MDMA-assisted therapy for posttraumatic stress disorder: a pooled analysis of ethnoracial differences in efficacy and safety from two phase 2 open-label lead-in trials and a phase 3 randomized, blinded placebo-controlled trial","volume":"36","author":"Ching","year":"2022","journal-title":"J Psychopharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/09687637.2020.1854688","article-title":"People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences","volume":"28","author":"Williams","year":"2021","journal-title":"Drugs Educ Prev Policy"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1556\/2054.2019.015","article-title":"The psychedelic renaissance and the limitations of a white-dominant medical framework: a call for indigenous and ethnic minority inclusion","volume":"4","author":"George","year":"2019","journal-title":"J Psychedelic Stud"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.2105\/AJPH.2013.301706","article-title":"A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific islanders","volume":"104","author":"George","year":"2014","journal-title":"Am J Public Health"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"774736","DOI":"10.3389\/fpsyt.2021.774736","article-title":"The need for psychedelic-assisted therapy in the black community and the burdens of its provision","volume":"12","author":"Smith","year":"2022","journal-title":"Frontiers in Psychiatry"},{"year":"2017","key":"ref39"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1096298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T04:27:51Z","timestamp":1681446471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1096298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":39,"alternative-id":["10.3389\/fpsyt.2023.1096298"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1096298","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1096298"}}